Kurma Partners is a key European venture capital group specialized in healthcare, with €470 million under management,  with two dedicated franchises : Kurma Biofund focused on therapeutic (current active fund KBIII) and Kurma Diagnostics focused on diagnostic and digital health (current active fund Kurma Dx2).  

STAT-Dx

Cardiologs

Minoryx Therapeutics

Advanced Perfusion Diagnostics

Amolyt Pharma

Asarina Pharma

Safe Orthopaedics

IO Biotech

Orphazyme

Corlieve Therapeutics

Dynacure

Pharvaris

Kurma Partners

Minoryx is a biotechnology company focused on the discovery and development of novel therapies for orphan diseases. The company's lead product candidate is leriglitazone (MIN-102), an orally bioavailable, brain-penetrant, small molecule that has been granted orphan drug status for the treatment of X-linked adrenoleukodystrophy (X-ALD).

Minoryx

COM:KURMAPARTNERS

Minoryx

Filings Not Available